Reviewing Anika Therapeutics Inc. (ANIK)’s and BioSpecifics Technologies Corp. (NASDAQ:BSTC)’s results

As Biotechnology companies, Anika Therapeutics Inc. (NASDAQ:ANIK) and BioSpecifics Technologies Corp. (NASDAQ:BSTC) are our subject to compare. And more specifically their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Anika Therapeutics Inc. 107.99M 4.87 19.07M 1.13 28.07
BioSpecifics Technologies Corp. 29.81M 15.63 16.51M 2.40 25.59

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Anika Therapeutics Inc. and BioSpecifics Technologies Corp. BioSpecifics Technologies Corp. has lower revenue, but higher earnings than Anika Therapeutics Inc. The business with a higher P/E ratio is currently more expensive of the two stocks. Anika Therapeutics Inc. is currently more expensive than BioSpecifics Technologies Corp., because it’s trading at a higher P/E ratio.

Profitability

Table 2 has Anika Therapeutics Inc. and BioSpecifics Technologies Corp.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Anika Therapeutics Inc. 17.66% 7.4% 6.9%
BioSpecifics Technologies Corp. 55.38% 21.8% 20.7%

Risk and Volatility

A beta of 1.86 shows that Anika Therapeutics Inc. is 86.00% more volatile than Standard and Poor’s 500. Competitively, BioSpecifics Technologies Corp.’s beta is 1.46 which is 46.00% more volatile than Standard and Poor’s 500.

Liquidity

Anika Therapeutics Inc. has a Current Ratio of 21 and a Quick Ratio of 18.5. Competitively, BioSpecifics Technologies Corp.’s Current Ratio is 48.4 and has 48.4 Quick Ratio. BioSpecifics Technologies Corp.’s better ability to pay short and long-term obligations than Anika Therapeutics Inc.

Analyst Ratings

In next table is given Anika Therapeutics Inc. and BioSpecifics Technologies Corp.’s ratings and recommmendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Anika Therapeutics Inc. 0 0 1 3.00
BioSpecifics Technologies Corp. 0 0 0 0.00

Insider and Institutional Ownership

Anika Therapeutics Inc. and BioSpecifics Technologies Corp. has shares held by institutional investors as follows: 93.2% and 59.3%. Anika Therapeutics Inc.’s share held by insiders are 0.2%. Competitively, 19.6% are BioSpecifics Technologies Corp.’s share held by insiders.

Performance

In this table we provide the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Anika Therapeutics Inc. -7.78% -17.27% -24.32% -26.66% -40.05% -41.07%
BioSpecifics Technologies Corp. 0.07% -3.28% 5.15% 43.88% 42.55% 41.73%

For the past year Anika Therapeutics Inc. had bearish trend while BioSpecifics Technologies Corp. had bullish trend.

Summary

On 9 of the 14 factors BioSpecifics Technologies Corp. beats Anika Therapeutics Inc.

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a woven gauze used as a bone graft wrap; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The companyÂ’s dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product used for the prevention of post-surgical spinal adhesions; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of DupuytrenÂ’s contracture and PeyronieÂ’s disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.